**Supplement 3**: Extended phenotypes definitions and MR results.

|  |  |  |
| --- | --- | --- |
| **Phenotype** | **Source of genetic variants** | |
| **Cohort** | **Participants** |
| 25OHD circulating levels | Manousaki *et al*22 | Meta-analysis of two 25OHD GWAS:   * 401,460 adult white British participants form the UKB24 * 42,274 from an international consortium of adult individuals of European ancestry25 |
| Covid-19 susceptibility | Extended Susceptibility | Meta-analysis of 13 GWAS performed in individuals of European ancestry from 8 countries:   * **Cases:** 6,232 individuals with Covid-19 by laboratory confirmation, chart review, or self-report * **Controls:** 960,163 individuals enrolled in the cohorts and not included as cases |
| Covid-19 severity | Extended Hospitalized | Meta-analysis of 6 GWAS performed in individuals of European ancestry from 6 countries:   * **Cases:** 2,900 hospitalized individuals with Covid-19 * **Controls:** 813,214 individuals enrolled in the cohorts and not included as cases |
| Extended Severe Disease | Meta-analysis of 2 GWAS performed in individuals of European ancestry from 2 countries:   * **Cases:** 620 Covid-19 infected hospitalized individuals who died or required respiratory support (intubation, CPAP, BiPAP, continuous external negative pressure, high flow nasal cannula). * **Controls:** 366,820 individuals enrolled in the cohorts and not included as cases |

**Table 2.1:** Sources of data for the analysis. Covid-19 susceptibility and severity outcomes are taken from the Covid-19 HGI36. See **Supplement 1** for details on cohorts of Covid-19 susceptibility and severity phenotypes.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Outcome** | **nSNPs** | **IVW OR (95% CI)** | **IVW p-value** | **Egger alpha** | **Alpha p-value** | **Egger OR (95% CI)** | **Egger p-value** |
| ***25OHD primary analysis*** | | | | | | | |
| Extended susceptibility | 94 | 0.89 (0.72, 1.09) | 0.26 | 0.01 (0.002, 0.02) | 0.02 | 0.69 (0.52, 0.93) | 0.02 |
| Extended hospitalization | 93 | 1.14 (0.82, 1.59) | 0.44 | 0.008 (-0.008, 0.02) | 0.34 | 0.97 (0.60, 1.55) | 0.89 |
| Extended severe disease | 95 | 1.80 (1.07, 3.04) | 0.03 | -0.01 (-0.04, 0.01) | 0.37 | 2.30 (1.09, 4.85) | 0.03 |
| ***25OHD sensitivity analysis restricted to genes in the vitamin D pathway*** | | | | | | | |
| Extended susceptibility | 20 | 0.80 (0.61, 1.05) | 0.10 | 0.02 (-0.008, 0.05) | 0.17 | 0.64 (0.43, 0.96) | 0.04 |
| Extended hospitalization | 20 | 1.08 (0.69, 1.69) | 0.74 | 0.05 (-0.00009, 0.10) | 0.06 | 0.67 (0.35, 1.26) | 0.23 |
| Extended severe disease | 20 | 2.39 (1.15, 4.96) | 0.02 | 0.01 (-0.07, 0.1) | 0.76 | 2.08 (0.66, 6.57) | 0.23 |
| ***25OHD sensitivity analysis after removal of SNPs identified by Phenoscanner*** | | | | | | | |
| Extended susceptibility | 18 | 0.69 (0.46, 1.02) | 0.06 | 0.03 (-0.008, 0.06) | 0.15 | 0.48 (0.27, 0.87) | 0.03 |
| Extended hospitalization | 18 | 1.13 (0.62, 2.05) | 0.69 | 0.03 (-0.03, 0.09) | 0.32 | 0.77 (0.30, 1.98) | 0.60 |
| Extended severe disease | 18 | 3.07 (1.17, 8.04) | 0.02 | -0.05 (-0.14, 0.04) | 0.29 | 6.03 (1.28, 28.4) | 0.04 |

**Table 2.2**: MR results for the extended phenotypes. nSNPs: number of SNPs retained for this analysis. CI: confidence interval.



**Figure 2.1**: Odds ratio point estimates and 95% confidence intervals for a one standard deviation increase in 25OHD levels on Covid-19 susceptibility and severity. Restricted: analysis restricted to SNPs near the 4 genes involved in known vitamin D metabolic pathways. Restricted-Phenoscanner: restricted analysis, with SNPs identified to have other associations in Phenoscanner removed.